An observational study in Age-related Macular Degeneration and Choroidal Neovascular Age-related Macular Degeneration, sponsored by Sequenom, Inc.. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-20.
Sponsored by Sequenom, Inc. · Observational
Subjects with wet AMD, dry AMD, and age-matched controls will undergo routine occular measurements, will provide a blood and cheek cell sample, and will have macular pigment optical density (MPOD) measured to determine if there is an association between genetics, MPOD and the risk of progression to wet AMD.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 45 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Sequenom, Inc. is the lead sponsor of 26 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Non-Hispanic Caucasian subjects 60 years of age and older diagnosed with either CNV or dry AMD and a cohort of age-matched controls
Exclusion Criteria:
Subjects diagnosed with CNV (AREDS Grade 4b)
Subjects diagnosed with dry AMD (AREDS Grade 3)
Subjects without AMD (AREDS Grade 1)
Association between a genetic variant in the CFH gene and risk of progression to CNV
DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate a genetic variant in the CFH gene and its association with risk of progression to CNV
Time frame: Baseline
Genetic correlation between MPOD and risk of progression to CNV
DNA extracted from blood and buccal cells collected from subjects with either CNV, dry AMD, and age-matched controls will be analyzed to investigate the correlation between genetics, MPOD, and risk of progression to CNV
Time frame: baseline
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sequenom, Inc.